Develops polymer-based drug delivery systems for sustained-release therapies, focusing on neurological disorders and pain management.
Serina Therapeutics, Inc. is a pioneering biotechnology firm focused on the development of therapeutic solutions for neurological diseases and pain management. At the forefront of its research efforts is SER 252, a promising POZ conjugate aimed at addressing the complexities of Parkinson's disease. The company's robust pipeline also includes SER 227, designed for long-acting pain relief, SER 214 targeting Parkinson's disease treatment, and SER 228, which holds potential for epilepsy management.
Beyond its primary therapeutic areas, Serina Therapeutics is advancing the application of POZ technology in lipid nanoparticle-delivered RNA vaccines, targeting infectious diseases. This innovative approach underscores the company's commitment to leveraging its scientific expertise in diverse biomedical fields.
Established in 2006 and headquartered in Huntsville, Alabama, Serina Therapeutics, Inc. continues to drive innovation in biopharmaceuticals, aiming to deliver transformative treatments that address unmet medical needs globally. With a strong foundation in research and development, the company remains dedicated to enhancing patient outcomes through cutting-edge therapeutic advancements.